Drugs / Replenine®-VF
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02250573 | Dec 2005 → Apr 2006 | hemophilia B | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02263469 | Aug 2005 → Jul 2006 | hemophilia B | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02263456 | Jul 1997 → Sep 2001 | hemophilia B | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02231944 | Jul 1997 → Oct 2003 | hemophilia B | Bio Products Laboratory | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Replenine-VF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02250573 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Replenine®-VF (High Purity Factor IX)” NCT02231944 ↗ |
| Route | Other | “administered in appropriate dosage by bolus infusion” NCT02250573 ↗ |